7-氨基-1,8-萘啶-2(1H)-酮硫酸盐 | 632620-24-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7-氨基-1,8-萘啶-2(1H)-酮硫酸盐
• 英文名称: 7-amino-1H-[1,8]naphthyridin-2-one sulfate
• 英文别名: 7-Amino-1,8-naphthyridin-2(1H)-one sulfate；7-amino-1H-1,8-naphthyridin-2-one;sulfuric acid
• CAS: 632620-24-7
• 化学式: C₈H₇N₃O*H₂O₄S
• 分子量: 259.243
• InChiKey: JEBQCMSNZMRCQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.15
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  151
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  7-氨基-1,8-萘啶-2(1H)-酮硫酸盐 在 吡啶 、 氢氟酸 、 sodium nitrite 作用下， 以90%的产率得到7-氟-1,8-萘啶-2-醇
  参考文献：
  名称：

  Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder

  摘要：

  The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D-2 partial agonists is described. Our goal was to optimize the affinities for the D-2, 5-HT2A and 5-HT1A receptors, such that the D-2/5-HT2A ratio was greater than 5 to ensure maximal occupancy of these receptors when the D-2 occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED = 0.3 mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1 mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.059
• 作为产物：
  描述：

  2,6-二氨基吡啶 以85的产率得到7-氨基-1,8-萘啶-2(1H)-酮硫酸盐
  参考文献：
  名称：

  Bioo. Med. Chem. Lett. 2011, 21, 2621-2625

  摘要：

  DOI：

文献信息

• 7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE
  申请人：Favor David Alan

  公开号：US20080167319A1

  公开（公告）日：2008-07-10

  This invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compound or a salt thereof, and its use as a medicament for the treatment of schizophrenia, bipolar disorder, or other central nervous system disorders.

  本发明涉及一种具有式(I)的化合物或其药用可接受的盐，包含该化合物或其盐的药物组合物，以及其作为治疗精神分裂症、双相情感障碍或其他中枢神经系统疾病的药物的用途。
• Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
  申请人：——

  公开号：US20030191315A1

  公开（公告）日：2003-10-09

  The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.

  本发明涉及制备外消旋2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮和(+)-2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮的方法。
• Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone
  申请人：Jennings Marie Sandra

  公开号：US20050288322A1

  公开（公告）日：2005-12-29

  The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.

  本发明涉及制备外消旋2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮和(+)-2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮的方法。
• Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone)
  申请人：Jennings Marie Sandra

  公开号：US20060194830A1

  公开（公告）日：2006-08-31

  The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.

  本发明涉及制备外消旋2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮和(+)2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮的方法。
• An Efficient and Cost-Effective Synthesis of Pagoclone
  作者：Timothy L. Stuk、Bryce K. Assink、Ronald C. Bates,、David T. Erdman、Victor Fedij、Sandra M. Jennings、Jennifer A. Lassig、Randy J. Smith、Traci L. Smith

  DOI：10.1021/op034060b

  日期：2003.11.1

  The compound (+)-2-(7-chloro-1,8-naphthyridin-2-yl)-3S-(5-methyl-2-oxohexyl)-1-isoindolinone (pagoclone) shows anxiolytic activity due to partial agonism of the benzodiazepine site of the GABA(A) receptor. We describe the development of an economical and practical process for a 100+ kg pilot plant production used to supply development needs. For the key reaction, a beta-keto phosphonium salt was prepared by selectively reacting a primary alpha-bromo ketone with triphenylphosphine in the presence of a secondary alpha-bromo ketone. A novel Wittig reaction with a 1-isoindolinone was used to produce racemic pagoclone. The enantiomerically pure drug substance was prepared by hydrolyzing a gamma-lactam and resolving the resulting enantiomeric carboxylic acids with (+)-ephedrine hemihydrate. An alternate resolution, involving chiral multicolumn chromatography (MCC) was also developed. The synthesis was completed by a racemization-free lactam formation to afford pagoclone.